Hanne Helfrich

TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations

Thorsten Zenz, Dominik Vollmer, Martin Trbušek et al. · Leukemia · 2010 · 164 citations

Medicine, Molecular Genetics, Oncology +16

<i>TP53</i> mutation and survival in aggressive B cell lymphoma

Thorsten Zenz, Markus Kreuz, Maxi Fuge et al. · International Journal of Cancer · 2017 · 98 citations · Full text

Medicine, Oncology, Cancer Genetics +9

MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma

Jennifer Hüllein, Mikołaj Słabicki, Maciej Rosołowski et al. · Cancer Research · 2019 · 38 citations · Full text

Veterinary Medicine, Molecular Genetics, Oncology +17

DNA damage–induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing

Julia Mohr, Hanne Helfrich, Maxi Fuge et al. · Blood · 2010 · 36 citations · Full text

Life Sciences, Molecular Biology, Oncology +14

TP53 Mutations and Outcome After Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial of the GCLLSG.

Thorsten Zenz, Patrick Hoth, Raymonde Busch et al. · Blood · 2009 · 15 citations

Medicine, Molecular Genetics, Oncology +11